Apixaban Dosing for Hemodynamically Stable Pulmonary Embolism
For acute treatment of stable PE, start apixaban at 10 mg orally twice daily for the first 7 days, then reduce to 5 mg twice daily for the remainder of the initial treatment phase (3-6 months). 1
Initial Treatment Phase (First 3-6 Months)
The FDA-approved dosing regimen for acute PE treatment is straightforward:
- Days 1-7: Apixaban 10 mg orally twice daily
- Day 8 onwards: Apixaban 5 mg orally twice daily
This dosing applies to hemodynamically stable PE patients and eliminates the need for parenteral anticoagulation bridging 1. The 7-day lead-in period with the higher dose (10 mg twice daily) is designed to rapidly achieve therapeutic anticoagulation and reduce recurrence risk 2.
Key Implementation Points
- The initial dose can be started 12-24 hours after any surgical procedure if PE is diagnosed perioperatively 1
- No routine laboratory monitoring is required
- For patients unable to swallow tablets, apixaban can be crushed and suspended in water, D5W, or apple juice, or mixed with applesauce 1
Extended Treatment Phase (Beyond 6 Months)
After completing 6 months of full-dose anticoagulation, reduce to apixaban 2.5 mg twice daily for extended secondary prevention. 2, 1
The 2026 AHA/ACC/ACCP guidelines provide Class 1A evidence that half-dose apixaban (2.5 mg twice daily) is recommended for extended treatment to reduce bleeding risk while maintaining efficacy 2. This recommendation is based on:
- The AMPLIFY-EXT trial showing apixaban 2.5 mg twice daily significantly reduced recurrent VTE compared to placebo with similar major bleeding rates 2
- The RENOVE trial demonstrating reduced-dose DOACs (including apixaban 2.5 mg twice daily) had lower bleeding rates (9.9% vs 15.2%) compared to full-dose, with similar VTE recurrence 2
- The API-CAT trial confirming this benefit even in high-risk cancer patients 2
Decision Algorithm for Extended Therapy Duration
Continue anticoagulation beyond 6 months if:
- First PE with no major reversible risk factor (unprovoked) - Class 1A recommendation 2
- PE with persistent risk factors (e.g., active cancer, thrombophilia) - Class 1C recommendation 2
Stop anticoagulation at 3-6 months if:
- PE due to major reversible risk factor (e.g., major surgery, major trauma, prolonged immobilization >3 days) - Class 1B recommendation 2
Shared decision-making for:
- PE with minor reversible risk factors (e.g., minor surgery, estrogen therapy, minor leg injury) - Class 2a recommendation 2
Special Circumstances
Drug Interactions
If the patient requires combined P-gp and strong CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir):
- Reduce 10 mg twice daily to 5 mg twice daily
- Reduce 5 mg twice daily to 2.5 mg twice daily
- Avoid these inhibitors entirely if patient is already on 2.5 mg twice daily 1
Note: Clarithromycin does not require dose adjustment despite being a combined inhibitor 1
Cancer-Associated PE
Use the same dosing regimen (10 mg twice daily for 7 days, then 5 mg twice daily) 2. DOACs including apixaban are recommended over warfarin (Class 1A) and are equivalent to LMWH for cancer-associated VTE 2, 3. The reduced dose (2.5 mg twice daily) after 6 months is particularly beneficial in cancer patients, reducing bleeding without compromising efficacy 2, 4.
Critical Pitfalls to Avoid
- Do not skip the 7-day lead-in period - The 10 mg twice daily dosing for the first week is essential for adequate initial anticoagulation
- Do not use 2.5 mg twice daily for acute treatment - This dose is only for extended prevention after completing at least 6 months of full-dose therapy 1
- Do not double-dose for missed doses - Simply take the next scheduled dose 1
- Avoid combined P-gp and strong CYP3A4 inducers (rifampin, carbamazepine, phenytoin, St. John's wort) as they significantly reduce apixaban levels 1